HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD

Andere talen Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Aandelen

600671

CNE000000BF3

slotkoers Shanghai S.E. Andere beurzen 00:00:00 05-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,65 ^CNY	+1,86%		+3,24%	-34,39%

04/07	Amoxicilline-clavulanaat-kaliumtabletten van Tianmushan Pharmaceutical voldoen aan de consistentie-evaluatie van de Chinese toezichthouder op geneesmiddelen	MT
24/05	Tianmushan Pharmaceutical Enterprise gaat productielijn vernieuwen voor 100 miljoen yuan	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Tianmushan Pharmaceutical's Amoxicillin Clavulanate Potassium Tablets Pass Chinese Drug Regulator's Consistency Evaluation	04/07
Tianmushan Pharmaceutical Enterprise to Revamp Production Line for 100 Million Yuan	24/05
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Qingdao Yuanjia Medical Treatment Technology proposal of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise was approved.	30-10-23
On October 19, 2023 Qingdao Yuanjia Medical Treatment Technology propose of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise.	19-10-23
TianMuShan Pharma Elects Chairman	16-10-23
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.	13-10-23
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.	13-10-23
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	10-10-23
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	30-08-23
TianMuShan Pharmaceutical CFO Steps Down	21-08-23
Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million.	21-08-23
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million.	21-08-23
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd announced that it expects to receive CNY 278.385575 million in funding from Qingdao Huilong Huaze Investment Co., Ltd.	18-08-23
Yongxin Huarui Proposes Board and Supervisory Board Nominations for Hangzhou Tianmushan's Board	14-05-23
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25-04-23
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	25-04-23
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Auditor Raises 'Going Concern' Doubt	25-04-23
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	30-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Aandelen

600671

CNE000000BF3

Andere talen

Filters